Literature DB >> 33268457

Topographic heterogeneity of lung microbiota in end-stage idiopathic pulmonary fibrosis: the Microbiome in Lung Explants-2 (MiLEs-2) study.

Eleanor Valenzi1, Haopu Yang2,3,4, John C Sembrat1, Libing Yang2,4, Spencer Winters1,5, Rachel Nettles2, Daniel J Kass1, Shulin Qin1,2, Xiaohong Wang1,2, Michael M Myerburg1, Barbara Methé1,2, Adam Fitch1,2, Jonathan K Alder1, Panayiotis V Benos3, Bryan J McVerry1,2, Mauricio Rojas1, Alison Morris1,2, Georgios D Kitsios6,2.   

Abstract

BACKGROUND: Lung microbiota profiles in patients with early idiopathic pulmonary fibrosis (IPF) have been associated with disease progression; however, the topographic heterogeneity of lung microbiota and their roles in advanced IPF are unknown.
METHODS: We performed a retrospective, case-control study of explanted lung tissue obtained at the time of lung transplantation or rapid autopsy from patients with IPF and other chronic lung diseases (connective tissue disease-associated interstitial lung disease (CTD-ILD), cystic fibrosis (CF), COPD and donor lungs unsuitable for transplant from Center for Organ Recovery and Education (CORE)). We sampled subpleural tissue and airway-based specimens (bronchial washings and airway tissue) and quantified bacterial load and profiled communities by amplification and sequencing of the 16S rRNA gene.
FINDINGS: Explants from 62 patients with IPF, 15 patients with CTD-ILD, 20 patients with CF, 20 patients with COPD and 20 CORE patients were included. Airway-based samples had higher bacterial load compared with distal parenchymal tissue. IPF basilar tissue had much lower bacterial load compared with CF and CORE lungs (p<0.001). No microbial community differences were found between parenchymal tissue samples from different IPF lobes. Dirichlet multinomial models revealed an IPF cluster (29%) with distinct composition, high bacterial load and low alpha diversity, exhibiting higher odds for acute exacerbation or death.
INTERPRETATION: IPF explants had low biomass in the distal parenchyma of all three lobes with higher bacterial load in the airways. The discovery of a distinct subgroup of patients with IPF with higher bacterial load and worse clinical outcomes supports investigation of personalised medicine approaches for microbiome-targeted interventions. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  bacterial infection; idiopathic pulmonary fibrosis; lung transplantation

Mesh:

Year:  2020        PMID: 33268457      PMCID: PMC8203183          DOI: 10.1136/thoraxjnl-2020-214770

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  41 in total

Review 1.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

2.  A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria.

Authors:  Soumitesh Chakravorty; Danica Helb; Michele Burday; Nancy Connell; David Alland
Journal:  J Microbiol Methods       Date:  2007-02-22       Impact factor: 2.363

3.  Radiographic Differentiation of Advanced Fibrocystic Lung Diseases.

Authors:  Masanori Akira
Journal:  Ann Am Thorac Soc       Date:  2017-03

Review 4.  Shotgun metagenomics, from sampling to analysis.

Authors:  Christopher Quince; Alan W Walker; Jared T Simpson; Nicholas J Loman; Nicola Segata
Journal:  Nat Biotechnol       Date:  2017-09-12       Impact factor: 54.908

5.  Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin.

Authors:  Sarah Knippenberg; Bianca Ueberberg; Regina Maus; Jennifer Bohling; Nadine Ding; Meritxell Tort Tarres; Heinz-Gerd Hoymann; Danny Jonigk; Nicole Izykowski; James C Paton; Abiodun D Ogunniyi; Sandro Lindig; Michael Bauer; Tobias Welte; Werner Seeger; Andreas Guenther; Thomas H Sisson; Jack Gauldie; Martin Kolb; Ulrich A Maus
Journal:  Thorax       Date:  2015-05-11       Impact factor: 9.139

6.  Role of gastroesophageal reflux symptoms in exacerbations of COPD.

Authors:  Ivan E Rascon-Aguilar; Mark Pamer; Peter Wludyka; James Cury; David Coultas; Louis R Lambiase; N Stanley Nahman; Kenneth J Vega
Journal:  Chest       Date:  2006-10       Impact factor: 9.410

7.  Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.

Authors:  David N O'Dwyer; Shanna L Ashley; Stephen J Gurczynski; Meng Xia; Carol Wilke; Nicole R Falkowski; Katy C Norman; Kelly B Arnold; Gary B Huffnagle; Margaret L Salisbury; MeiLan K Han; Kevin R Flaherty; Eric S White; Fernando J Martinez; John R Erb-Downward; Susan Murray; Bethany B Moore; Robert P Dickson
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

Review 8.  Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis.

Authors:  Robert Brownell; Naftali Kaminski; Prescott G Woodruff; Williamson Z Bradford; Luca Richeldi; Fernando J Martinez; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2016-06-01       Impact factor: 21.405

Review 9.  New opportunities for managing acute and chronic lung infections.

Authors:  William O C M Cookson; Michael J Cox; Miriam F Moffatt
Journal:  Nat Rev Microbiol       Date:  2017-10-24       Impact factor: 60.633

10.  Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.

Authors:  Richard J Allen; Joanne Porte; Rebecca Braybrooke; Carlos Flores; Tasha E Fingerlin; Justin M Oldham; Beatriz Guillen-Guio; Shwu-Fan Ma; Tsukasa Okamoto; Alison E John; Ma'en Obeidat; Ivana V Yang; Amanda Henry; Richard B Hubbard; Vidya Navaratnam; Gauri Saini; Norma Thompson; Helen L Booth; Simon P Hart; Mike R Hill; Nik Hirani; Toby M Maher; Robin J McAnulty; Ann B Millar; Philip L Molyneaux; Helen Parfrey; Doris M Rassl; Moira K B Whyte; William A Fahy; Richard P Marshall; Eunice Oballa; Yohan Bossé; David C Nickle; Don D Sin; Wim Timens; Nick Shrine; Ian Sayers; Ian P Hall; Imre Noth; David A Schwartz; Martin D Tobin; Louise V Wain; R Gisli Jenkins
Journal:  Lancet Respir Med       Date:  2017-10-20       Impact factor: 102.642

View more
  5 in total

Review 1.  The lung microbiome: progress and promise.

Authors:  Samantha A Whiteside; John E McGinniss; Ronald G Collman
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

Review 2.  The Role of Microbiome and Virome in Idiopathic Pulmonary Fibrosis.

Authors:  Paschalis Ntolios; Vassilios Tzilas; Evangelos Bouros; Eleni Avdoula; Ioannis Karakasiliotis; Demosthenes Bouros; Paschalis Steiropoulos
Journal:  Biomedicines       Date:  2021-04-20

3.  Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor Lungs.

Authors:  Gisli G Einarsson; Bart M Vanaudenaerde; Christopher D Spence; Andrew J Lee; Mieke Boon; Geert M Verleden; J Stuart Elborn; Lieven J Dupont; Dirk Van Raemdonck; Deirdre F Gilpin; Robin Vos; Stijn E Verleden; Michael M Tunney
Journal:  Front Cell Infect Microbiol       Date:  2022-03-16       Impact factor: 5.293

4.  IPF-Acute Exacerbations: Advances and Future Perspectives.

Authors:  Spyros A Papiris; Lykourgos Kolilekas; Konstantinos Kagouridis; Maria Maniati; Effrosyni D Manali
Journal:  Front Pharmacol       Date:  2022-04-14       Impact factor: 5.988

Review 5.  Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.

Authors:  Francesco Amati; Anna Stainer; Marco Mantero; Andrea Gramegna; Edoardo Simonetta; Giulia Suigo; Antonio Voza; Anoop M Nambiar; Umberto Cariboni; Justin Oldham; Philip L Molyneaux; Paolo Spagnolo; Francesco Blasi; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.